Prospective Study of Autologous Adipose Derived Stromal Vascular Fraction Containing Stem Cells for the Treatment of Knee Osteoarthritis
Mark Berman, MD, Elliot Lander, MD, Thomas Grogan, MD, Walter O'Brien, MD, Jonathan Braslow, MD, Shawntae Dowell and Sean Berman, MS
Article Type: Original Article | First Published: November 29, 2019
The management of osteoarthritis of the knee runs the spectrum of care from a variety of conservative treatments often culminating in total joint arthroplasty. We initiated a large prospective study to evaluate whether autologous adipose derived stromal vascular fraction (SVF - rich in stem cells) therapy is a safe and effective option. A patient funded prospective study of 2,586 patients from a network of physicians participated in an IRB approved study using autologous stromal vascular fractio...
Selection of Cells for Parkinson's Disease Cell-Therapy
Ashok Chakraborty and Anil Diwan
Article Type: Research Article | First Published: November 25, 2019
Availability of DOPA in situ and thereafter Dopamine (DA) is the main therapeutic approach to treat the Parkinson's Disease (PD). Human neural stem cells (hNSCs), a good source of DA synthesis and release, have long been demonstrated to be a promising candidate for treating PD. However limited cell sourcing and low-growth rate are major concern of its applicability. Different types of other stem cells or reprogrammed somatic cells, including induced pluripotent stem cells (iPSCs), holds tremendo...
Mesenchymal Stem Cell Based Therapy for Parkinson's Disease
Neveen A Salem
Article Type: Review Article | First Published: September 23, 2019
Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology, the predominant pathology of PD is the loss of dopaminergic cells in the substantia nigra. It is characterized by hallmark signs of bradykinesia, rigidity, tremor, and postural instability. Medical and pharmacological treatments for Parkinson's disease are limited to the symptomatic relief of patients, and has failed to prevent or slow down the process of neurodegeneration. Cell transpla...
Human Umbilical Cord Stem Cells in Chitosan Attenuate Myocardial Injury in Rat Cardiac Infarction
Robert J Henning MD, Abraham Khan MD and Xiao Wang MD
Article Type: Original Article | First Published: June 24, 2019
Myocardial infarction (MI) is the leading cause of cardiovascular deaths and disability in the industrialized world. Although stem cells have been injected into hearts to limit MI damage, < 4% of stem cells remain in the heart for > 1 hour due to myocardial contractility which causes the rapid egress of the stem cells through the cardiac veins and lymphatics. We hypothesized that stem cells in chitosan gels would remain longer in the heart and therefore be more beneficial in MI repair....
Potential of Polycaprolactone Nanofiber Scaffold for Ex Vivo Expansion of Cord Blood-Derived CD34+ Hematopoietic Stem Cells
Seyed Hadi Mousavi, Saeid Abroun, Masoud Soleimani and Seyed Javad Mowla
Article Type: Research Article | First Published: February 07, 2019
An efficient and practical ex vivo expansion of cord blood hematopoietic stem cells as an alternative source of HSC transplantation is crucial in understanding the potential of HSC transplantation in treating or supportive therapy in a variety of hematologic and non-hematologic disorders. The aim of this study was an ex vivo expansion of cord blood hematopoietic stem cells in a novel three-dimensional polycaprolactone nanofiber scaffold coated with collagen....